role,name,affiliation,address,trial_id,processed_name,first_name,gender,gender_probability,gender_sample_count,Rank,NCT Number,Title,Status,Study Results,Conditions,Interventions,First Posted,Locations,URL
Principal Investigator,"Ryan Bradley, ND, MPH","University of California, San Diego",,NCT04386187,ryan bradley,ryan,male,0.99,45164,1,NCT04386187,Glutathione-rich Foods for Type 2 Diabetes,Not yet recruiting,No Results Available,Type 2 Diabetes,Other: GSH Foods|Other: Nutrition education about glutathione sources in the diet|Other: Standard of care nutrition education for type 2 dabetes,"May 13, 2020",,https://ClinicalTrials.gov/show/NCT04386187
Principal Investigator,"Sujeet Jha, MRCP","Prinicipal Director, Institute of Endocrinology & Metabolism, Maxhealthcare",,NCT04363710,sujeet jha,sujeet,male,0.99,151,7,NCT04363710,Prospective Interventional Study on Reversibility of Type 2 Diabetes Mellitus With Hypocaloric Diet,Completed,No Results Available,Type 2 Diabetes Mellitus in Obese,Other: Low Calorie Diet,"April 27, 2020","Max Healthcare, New Delhi, Delhi, India",https://ClinicalTrials.gov/show/NCT04363710
Principal Investigator,"Habiba I. Ali, PhD, RD,CDE",United Arab Emirates University,,NCT04264793,habiba i. ali,habiba,female,0.97,2077,9,NCT04264793,Skills for Change: Nutrition Education Program for Emirati Adults With Type 2 Diabetes,Completed,No Results Available,Type 2 Diabetes,Behavioral: Behavioral Lifestyle Intervention|Behavioral: Usual Care,"February 11, 2020","Ambulatory Healthcare Services, SEHA, Al Ain, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04264793
Principal Investigator,"Filip K Knop, Professor, MD","Director of Center for Clinical Metabolic Research, Gentofte Hospital",,NCT04228484,filip k knop,filip,male,0.98,23771,10,NCT04228484,The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes,Recruiting,No Results Available,Type2 Diabetes,Drug: Insulin|Drug: Empagliflozin|Drug: Metformin,"January 14, 2020","Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup, Capital Region, Denmark",https://ClinicalTrials.gov/show/NCT04228484
Principal Investigator,"Jeffrey Berger, MD",NYU Langone Health,,NCT04369664,jeffrey berger,jeffrey,male,0.99,22034,14,NCT04369664,CHOlesterol Lowering and Residual Risk in Type 2 Diabetes,Recruiting,No Results Available,Type 2 Diabetes,Drug: Statin|Drug: PCSK9 inhibitor,"April 30, 2020","NYU Langone Health, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04369664
Principal Investigator,"Roselle Herring, MD PhD","CEDAR, Royal Surrey County Hospital",,NCT04219124,roselle herring,roselle,female,0.98,486,18,NCT04219124,"The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes",Recruiting,No Results Available,Type 2 Diabetes,Drug: IMP oral tablet|Drug: Placebo oral tablet,"January 6, 2020","CEDAR, Royal Surrey County Hospital, Guildford, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT04219124
Study Chair,"Mellanie Davis, MD PhD",University of Leicester,,NCT04219124,mellanie davis,mellanie,female,0.99,225,18,NCT04219124,"The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes",Recruiting,No Results Available,Type 2 Diabetes,Drug: IMP oral tablet|Drug: Placebo oral tablet,"January 6, 2020","CEDAR, Royal Surrey County Hospital, Guildford, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT04219124
Principal Investigator,"Nanna Lind, RN MSc",Steno Diabetes Center Copenhagen,,NCT04331444,nanna lind,nanna,female,0.95,1267,19,NCT04331444,Steno2tech - Continuous Glucose Monitoring and Type 2 Diabetes.,Not yet recruiting,No Results Available,Type 2 Diabetes Treated With Insulin,Device: CGM|Behavioral: training course|Behavioral: Peer-support,"April 2, 2020",,https://ClinicalTrials.gov/show/NCT04331444
Principal Investigator,fengyi Yuan,Shenzhen People' hospital,,NCT04426422,fengyi yuan,fengyi,male,0.89,9,20,NCT04426422,Effect of Metformin on Gut Microbiota Changes and Glycemic Control of Newly Diagnosed Type 2 Diabetes,Completed,No Results Available,Type 2 Diabetes,Drug: Metformin Hydrochloride,"June 11, 2020","Shenzhen People' S Hospital, Shenzhen, Guangdong, China",https://ClinicalTrials.gov/show/NCT04426422
Study Chair,"George Szewczyk, PhD",BioKier Inc.,,NCT04279444,george szewczyk,george,male,0.98,65488,21,NCT04279444,Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients,Not yet recruiting,No Results Available,Type 2 Diabetes,Dietary Supplement: BKR-017,"February 21, 2020","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",https://ClinicalTrials.gov/show/NCT04279444
Study Director,"Michael Roden, Prof. Dr.",German Diabetes Center,,NCT04222231,michael roden,michael,male,0.99,245870,25,NCT04222231,RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes,Enrolling by invitation,No Results Available,Type 2 Diabetes,Other: Blood-flow restriction resistance training|Other: Classical resistance training,"January 9, 2020","German Diabetes Center, Düsseldorf, NRW, Germany",https://ClinicalTrials.gov/show/NCT04222231
Principal Investigator,"wang congrong, doctor",Shanghai East Hospital. China.,,NCT04441658,wang congrong,wang,male,0.64,3532,28,NCT04441658,Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Type 2 Diabetes Mellitus,Recruiting,No Results Available,Type 2 Diabetes|Mesenchymal Stem Cells,Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: saline,"June 22, 2020","Shanghai East Hospital, Shanghai Tongji University, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04441658
Principal Investigator,Mu,Chinese PLA General Hospital,,NCT04217291,mu,mu,male,0.66,824,31,NCT04217291,The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: SY-004|Other: SY-004 matching placebo,"January 3, 2020","PLA General Hospital, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04217291
Principal Investigator,"Fajriansyah Fajriansyah, Master",Faculty of Pharmacy Universitas Padjadjaran Bandung,,NCT04313829,fajriansyah fajriansyah,fajriansyah,male,1.0,2,32,NCT04313829,Pharmacist Counseling on the Health-related Quality of Life of Patients With Type 2 Diabetes Mellitus,Completed,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Pharmacist Counseling Intervention,"March 18, 2020","Puskesmas Antang, Makassar, South Sulawesi, Indonesia|Puskesmas Batua, Makassar, South Sulawesi, Indonesia|Puskesmas Jongaya, Makassar, South Sulawesi, Indonesia|Puskesmas Tamalanrea, Makassar, South Sulawesi, Indonesia",https://ClinicalTrials.gov/show/NCT04313829
Principal Investigator,"Catherine Anastasopoulou, MD, PhD",Albert Einstein Healthcare Network,,NCT04277780,catherine anastasopoulou,catherine,female,0.98,50312,35,NCT04277780,Reducing Emergency Department Visits and Improving Glucose Control in Uncontrolled Type 2 Diabetes Using CGM Sensors at Hospital Discharge,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Device: Continuous Glucose Monitoring Sensor|Other: Diabetes Management Instructions,"February 20, 2020","Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04277780
Study Director,Kun Lou,"Department of medicine, CSPC clinical development division",,NCT04218734,kun lou,kun,male,0.78,1297,36,NCT04218734,A Study to Evaluate the Efficacy and Safety of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With Type 2 Diabetes Mellitus,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Drug: DBPR108|Drug: metformin hydrochloride|Drug: placepo,"January 6, 2020",,https://ClinicalTrials.gov/show/NCT04218734
Study Director,"Victor Kravchenko, PhD, Prof",V.P.Komisarenko Institute of Endocrinology and Metabolism,,NCT04283201,victor kravchenko,victor,male,0.99,94927,38,NCT04283201,Type 2 Diabetes Mellitus Prevention Ukraine,"Active, not recruiting",No Results Available,Evaluation of Lifestyle Modification for the Prevention of Type 2 Diabetes,Other: Lifestyle modification,"February 25, 2020","V.P.Komisarenko Institute of Endocrinology and Metabolism, Kyiv, Ukraine",https://ClinicalTrials.gov/show/NCT04283201
Study Director,John Chen,"Neurotronic, Inc.",,NCT04232774,john chen,john,male,0.99,218952,39,NCT04232774,Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities,Recruiting,No Results Available,Type 2 Diabetes Mellitus With Circulatory Complciation,Device: The Neurotronic arterial ablation catheter,"January 18, 2020","Sanatorio Italiano - Centro de Intervenciones Endovasculares, Asunción, Paraguay",https://ClinicalTrials.gov/show/NCT04232774
Principal Investigator,"John L Sievenpiper, MD,PhD,FRCPC",University of Toronto,,NCT04245826,john l sievenpiper,john,male,0.99,218952,219,NCT04245826,Meta-analysis of Low-calorie Sweetened Beverages and Cardiometabolic Outcomes,"Active, not recruiting",No Results Available,Adiposity|Metabolic Syndrome|Type 2 Diabetes|Cardiovascular Diseases|Mortality,Other: Change in LCSBs Intake|Other: Substitute LCSBs for SSBs or Water,"January 29, 2020","Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04245826
Principal Investigator,"John L Sievenpiper, MD,PhD,FRCPC",University of Toronto,,NCT04327713,john l sievenpiper,john,male,0.99,218952,224,NCT04327713,Meta-analysis of Fish Oil Supplementation and Cardiovascular Outcomes in Diabetes,"Active, not recruiting",No Results Available,Type2 Diabetes|Heart Failure|Myocardial Infarction|Stroke|Arrhythmia|Cardiovascular Diseases,Dietary Supplement: fish oil supplement,"March 31, 2020","Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada",https://ClinicalTrials.gov/show/NCT04327713
Principal Investigator,"Nadine Mansour, MD","Al-Agouza Family Medicine Center & Faculty of Medicine, Cairo University",,NCT04214600,nadine mansour,nadine,female,0.98,55786,41,NCT04214600,Cognitive Behavioral Therapy for Adherence in Patients With Type 2 Diabetes,"Active, not recruiting",No Results Available,Type 2 Diabetes|Depression,Behavioral: Cognitive Behavioral Therapy (CBT),"January 2, 2020","Al-Agouza Family Medicine Center (AFMC)., Agouza, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04214600
Principal Investigator,"Anne L Peters, MD",University of Southern California,,NCT04228003,anne l peters,anne,female,0.97,78727,42,NCT04228003,Pendulum D2D Glucose Control for Adults With Type 2 Diabetes,Not yet recruiting,No Results Available,Type2 Diabetes|Gastrointestinal Symptoms,Dietary Supplement: Pendulum Glucose Control formulation for T2D,"January 14, 2020","USC Westside Center for Diabetes, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04228003
Principal Investigator,"Alma Au, PhD","Applied Social Sciences, Hong Kong Polytechnic University",,NCT04261361,alma au,alma,female,0.95,9312,43,NCT04261361,Cognitive Behavioural Therapy for Adherence and Sub-clinical Depression for Type 2 Diabetes,Recruiting,No Results Available,Type 2 Diabetes|Depression,Behavioral: CBT-AD intervention|Behavioral: Adherence counseling|Behavioral: Psycho-education package,"February 7, 2020","Applied Social Sciences, Hong Kong Polytechnic University, Hong Kong, Hong Kong|Institute of Active Ageing, Kowloon, Hong Kong",https://ClinicalTrials.gov/show/NCT04261361
Principal Investigator,"Ian Wilkinson, MD",University of Cambridge,,NCT04307797,ian wilkinson,ian,male,0.99,27117,44,NCT04307797,Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes,Not yet recruiting,No Results Available,Type2 Diabetes|Obesity,Drug: 0.9% Sodium-chloride|Drug: Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min,"March 13, 2020",,https://ClinicalTrials.gov/show/NCT04307797
Principal Investigator,"Usune Etxeberria, PhD",Basque Culinary Center Fundazioa,,NCT04449120,usune etxeberria,usune,female,1.0,2,46,NCT04449120,HOME COOKING: Health Empowerment Strategy in People With Type II Diabetes Mellitus,Recruiting,No Results Available,Type 2 Diabetes Mellitus,Behavioral: Mediterranean diet-based culinary intervention|Behavioral: Mediterranean diet-based nutritional education intervention,"June 26, 2020","Basque Culinary Center, Donostia-San Sebastian, Guipuzcoa, Spain",https://ClinicalTrials.gov/show/NCT04449120
Principal Investigator,"Ville Wallenius, Ass. Prof.","Sahlgrenska University Hospital, Sweden",,NCT04314427,ville wallenius,ville,male,0.98,3245,49,NCT04314427,Early Glycaemic Control in Type 2 Diabetes Patients After Bariatric Surgery; ECODABS,Completed,No Results Available,Diabetes Mellitus Type 2 in Obese,Procedure: Roux-en-Y gastric bypass|Procedure: Sleeve gastrectomy,"March 19, 2020","Antwerp University Hospital, Antwerp, Edegem, Belgium|Universitair Ziekenhuis, Brussel, Jette, Belgium|Gent University Hospital, Gent, Belgium|Hospital Clinico San Carlos, Madrid, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Sahlgrenska University Hospital, Gothenburg, Sweden|Karolinska Institutet, Stockholm, Sweden|South kensington campus, London, United Kingdom",https://ClinicalTrials.gov/show/NCT04314427
Principal Investigator,"Chris Nadege NGANOU-GNINDJIO, MD, MAS",Yaounde Central Hospital,,NCT04222738,chris nadege nganou-gnindjio,chris,male,0.9,156083,50,NCT04222738,The Cardiovascular Effects of Ginger (Zingiber Officinale) in Patients With Type II Diabetes Mellitus,Completed,No Results Available,Cardiovascular Benefits of Zingiber Officinale Roscoe in Patients With Type 2 Diabetes Mellitus Before and After 6 Weeks of add-on Therapy,Dietary Supplement: GINOFF1,"January 10, 2020","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",https://ClinicalTrials.gov/show/NCT04222738
Study Director,"Eugene SOBNGWI, Professor",Yaounde Central Hospital,,NCT04222738,eugene sobngwi,eugene,male,0.95,8915,50,NCT04222738,The Cardiovascular Effects of Ginger (Zingiber Officinale) in Patients With Type II Diabetes Mellitus,Completed,No Results Available,Cardiovascular Benefits of Zingiber Officinale Roscoe in Patients With Type 2 Diabetes Mellitus Before and After 6 Weeks of add-on Therapy,Dietary Supplement: GINOFF1,"January 10, 2020","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",https://ClinicalTrials.gov/show/NCT04222738
Study Chair,"Jean Claude MBANYA, Professor",Yaounde Central Hospital,,NCT04222738,jean claude mbanya,jean,male,0.95,196185,50,NCT04222738,The Cardiovascular Effects of Ginger (Zingiber Officinale) in Patients With Type II Diabetes Mellitus,Completed,No Results Available,Cardiovascular Benefits of Zingiber Officinale Roscoe in Patients With Type 2 Diabetes Mellitus Before and After 6 Weeks of add-on Therapy,Dietary Supplement: GINOFF1,"January 10, 2020","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",https://ClinicalTrials.gov/show/NCT04222738
Principal Investigator,"Chris Nadege NGANOU-GNINDJIO, MD, MAS",Yaounde Central Hospital,,NCT04222686,chris nadege nganou-gnindjio,chris,male,0.9,156083,81,NCT04222686,Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: Perindopril Arginine|Drug: Losartan Potassium,"January 10, 2020","Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon",https://ClinicalTrials.gov/show/NCT04222686
Principal Investigator,"Chong Lee, Ph.D.",Arizona State University,,NCT04268212,chong lee,chong,male,0.71,2092,51,NCT04268212,An Alternative Approach to Improve Hyperglycemia Among Type 2 Diabetes Patients,Completed,No Results Available,Type2 Diabetes,Dietary Supplement: Bitter melon juice (100 ml)|Behavioral: Exercise,"February 13, 2020",,https://ClinicalTrials.gov/show/NCT04268212
Principal Investigator,"Daniela Jakubowicz, MD",Wolfson Medical Center,,NCT04405895,daniela jakubowicz,daniela,female,0.98,109997,53,NCT04405895,Effect of Meal Timing in T2D on Hepatocytes SRIT1 and Clock Genes,Not yet recruiting,No Results Available,Type 2 Diabetes|Obesity,Other: Breakfast Diet|Other: Allday Diet,"May 28, 2020","Wolfson Medical Center, Holon, Please Select, Israel",https://ClinicalTrials.gov/show/NCT04405895
Principal Investigator,"Shani Tsameret, RD",E. Wolfson Medical Center.,,NCT04405895,shani tsameret,shani,male,0.63,1254,53,NCT04405895,Effect of Meal Timing in T2D on Hepatocytes SRIT1 and Clock Genes,Not yet recruiting,No Results Available,Type 2 Diabetes|Obesity,Other: Breakfast Diet|Other: Allday Diet,"May 28, 2020","Wolfson Medical Center, Holon, Please Select, Israel",https://ClinicalTrials.gov/show/NCT04405895
Principal Investigator,"Riccardo Bonadonna, MD",Azienda Ospedaliero-Universitaria di Parma,,NCT04271189,riccardo bonadonna,riccardo,male,0.99,36394,54,NCT04271189,Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs,Not yet recruiting,No Results Available,Newly Diagnosed Type 2 Diabetes,Drug: Metformin-Sitagliptin-Empaglifozin-Pioglitazone|Drug: Standard of care,"February 17, 2020","Azienda Ospedaliero Universitaria, Parma, Italy",https://ClinicalTrials.gov/show/NCT04271189
Principal Investigator,"Mirac Vural Keskinler, MD",IMU Doctoral program,,NCT04392570,mirac vural keskinler,mirac,male,0.9,514,57,NCT04392570,The Effect of Fasting on Serum Osmolarity in Diabetic Patients,Completed,No Results Available,Type2 Diabetes,Diagnostic Test: Fasting,"May 19, 2020","IMU Goztepe Education and Research Hospital, Istanbul, Kadikoy, Turkey",https://ClinicalTrials.gov/show/NCT04392570
Principal Investigator,"Mary A. Steinhardt, EdD",University of Texas at Austin,,NCT04282395,mary a. steinhardt,mary,female,0.99,142684,59,NCT04282395,Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: Resilience-Based Diabetes Self-Management Education|Behavioral: Standard Diabetes Self-Management Education,"February 24, 2020","University of Texas at Austin, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04282395
Principal Investigator,"Sharon A. Brown, PhD",University of Texas at Austin,,NCT04282395,sharon a. brown,sharon,female,0.98,33532,59,NCT04282395,Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: Resilience-Based Diabetes Self-Management Education|Behavioral: Standard Diabetes Self-Management Education,"February 24, 2020","University of Texas at Austin, Austin, Texas, United States",https://ClinicalTrials.gov/show/NCT04282395
Principal Investigator,"Mary O Whipple, PhD","University of Colorado, Denver",,NCT04262128,mary o whipple,mary,female,0.99,142684,125,NCT04262128,Sedentary Behavior in Older Women With and Without Type 2 Diabetes,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Healthy",,"February 10, 2020","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",https://ClinicalTrials.gov/show/NCT04262128
Principal Investigator,"Eleni Hatzidimitriadou, PhD",Canterbury Christ Church University,,NCT04274660,eleni hatzidimitriadou,eleni,female,0.98,7342,62,NCT04274660,Evaluation of Diabetes and WELLbeing Programme,Recruiting,No Results Available,Type 2 Diabetes|Type 2 Diabetes Treated With Insulin,Behavioral: DWELL (Diabetes and WELLbeing) Programme,"February 18, 2020","Arteveldehogeschool, Ghent, Belgium|Centre Hosptalier Douai, Douai, France|Kinetic Analysis, Breda, 's-Hertogenbosch, Netherlands|Medway Community Healthcare, Gillingham, Kent, United Kingdom|Blackthorn Trust, Maidstone, Kent, United Kingdom",https://ClinicalTrials.gov/show/NCT04274660
Principal Investigator,"Linda Snetselaar, PhD, RD, LD",University of Iowa,,NCT04311853,linda snetselaar,linda,female,0.98,99198,63,NCT04311853,Evidence-Based Nutrition Practice Guidelines of Toolkit and Preliminary Outcomes,Completed,No Results Available,Type 2 Diabetes Mellitus,,"March 17, 2020",,https://ClinicalTrials.gov/show/NCT04311853
Principal Investigator,"Esther F Myers, PhD, RD",Academy of Nutrition and Dietetics,,NCT04311853,esther f myers,esther,female,0.99,43885,63,NCT04311853,Evidence-Based Nutrition Practice Guidelines of Toolkit and Preliminary Outcomes,Completed,No Results Available,Type 2 Diabetes Mellitus,,"March 17, 2020",,https://ClinicalTrials.gov/show/NCT04311853
Principal Investigator,"Smita Rao, PhD",NYU Langone Health,,NCT04383314,smita rao,smita,female,0.98,347,65,NCT04383314,Targeting Hyaluronan Accumulation Through Exercise in T2DM,Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,Behavioral: 10-week exercise program on HA accumulation,"May 12, 2020",,https://ClinicalTrials.gov/show/NCT04383314
Study Director,"Kadir Kayataş, associate professor",Haydarpaşa Numune Education and Research Hospital,,NCT04298515,kadir kayataş,kadir,male,0.97,47087,66,NCT04298515,"Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity",Recruiting,No Results Available,Type 2 Diabetes|Insulin Resistance|Obesity|Nesfatin-1,Diagnostic Test: Nesfatin-1,"March 6, 2020","Haydarpaşa Numune Education and Research Hospital, İstanbul, Turkey",https://ClinicalTrials.gov/show/NCT04298515
Principal Investigator,"Boyu Li, PHD",Beijing Chao Yang Hospital,,NCT04303819,boyu li,boyu,male,0.81,26,67,NCT04303819,The Effect of Exenatide on Fasting Bile Acids,Completed,No Results Available,Type 2 Diabetes Mellitus in Obese,Drug: Exenatide treatment,"March 11, 2020","Beijing Chao-yang hospital, Beijing, China",https://ClinicalTrials.gov/show/NCT04303819
Principal Investigator,ICE Y PURI,Andalas University,,NCT04440319,ice y puri,ice,male,0.67,4443,68,NCT04440319,Diabetes Nutrition Education With Glycemic Control,Enrolling by invitation,No Results Available,Type2 Diabetes Mellitus,Behavioral: Intervention group,"June 19, 2020","Ice Yolanda Puri, Padang, WEST Sumatera, Indonesia",https://ClinicalTrials.gov/show/NCT04440319
Principal Investigator,"Gianluca Iacobellis, MD PhD",University of Miami,,NCT04341935,gianluca iacobellis,gianluca,male,0.99,41833,69,NCT04341935,Effects of DPP4 Inhibition on COVID-19,Not yet recruiting,No Results Available,Coronavirus Infection|Type 2 Diabetes,Drug: Linagliptin|Drug: Insulin regimen,"April 10, 2020","University of Miami, Miami, Florida, United States",https://ClinicalTrials.gov/show/NCT04341935
Study Director,"Song Ding, MD","Department of Cardiology, Ren Ji Hospital",,NCT04390711,song ding,song,male,0.69,2068,70,NCT04390711,Association of Carbamylated HDL and CAD in T2DM Patients,Completed,No Results Available,Type 2 Diabetes Mellitus With Circulatory Complciation,"Other: High density lipoprotein isolation, detection and in-vitro study.","May 15, 2020","Rui Jin Hospital, Shanghai, China",https://ClinicalTrials.gov/show/NCT04390711
Principal Investigator,"Harald Sourij, MD","Medical University of Graz, Auenbruggerplatz 15",,NCT04283318,harald sourij,harald,male,0.99,6762,71,NCT04283318,"Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes",Recruiting,No Results Available,Healthy|Obesity|Type 2 Diabetes Mellitus|Type 1 Diabetes,Behavioral: 12h fasting|Behavioral: 36h fasting,"February 25, 2020","Medical University of Graz, Graz, Austria",https://ClinicalTrials.gov/show/NCT04283318
Principal Investigator,"Dr.Holly Blake, PhD",University of Nottingham,,NCT04243174,holly blake,holly,female,0.87,4247,72,NCT04243174,The Use of Short SMS Messaging With Type 2 Diabetes (T2DM),Completed,No Results Available,Type 2 Diabetes|Physical Exercise,Behavioral: SMS Messaging,"January 28, 2020","King Fahd Medical City, Riyadh, Saudi Arabia",https://ClinicalTrials.gov/show/NCT04243174
Principal Investigator,"Valentine Yanchou Njike, MD, MPH",Yale-Griffin Prevention Reserach Center,,NCT04316429,valentine yanchou njike,valentine,female,0.72,6456,74,NCT04316429,"The Impact of Consumption of Eggs in the Context of Plant-Based Diets on Endothelial Function, Diet Quality, and Cardio-Metabolic Risk Factors in Adults at Risk for Type 2 Diabetes",Recruiting,No Results Available,Type 2 Diabetes|Cardiovascular Diseases,Other: Egg included vegan phase|Other: Vegan Phase,"March 20, 2020","Yale-Griffin Prevention Research Center, Derby, Connecticut, United States",https://ClinicalTrials.gov/show/NCT04316429
Principal Investigator,"Pradana Soewondo, Prof",Fakultas Kedokteran Universitas Indonesia,,NCT04289818,pradana soewondo,pradana,male,1.0,25,75,NCT04289818,"The Effectiveness of ""CARE Coaching Model"" as an Effort to Empower Type 2 Diabetes Mellitus Patients","Active, not recruiting",No Results Available,Diabetes Type 2,Other: Health Coaching,"February 28, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04289818
Principal Investigator,"Pradana Soewondo, Prof",Fakultas Kedokteran Universitas Indonesia,,NCT04271631,pradana soewondo,pradana,male,1.0,25,168,NCT04271631,"Integration of Education Based-Application and ""CARE Coaching Model"" in Management of Type 2 Diabetes Mellitus Patients Using Insulin","Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Other: Mobile Application-Based Diabetes Education|Other: Health Coaching,"February 17, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",https://ClinicalTrials.gov/show/NCT04271631
Principal Investigator,"Paolo Fiorina, MD, PhD",University of Milan,,NCT04272359,paolo fiorina,paolo,male,0.99,102713,77,NCT04272359,Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus,Recruiting,No Results Available,"T2DM (Type 2 Diabetes Mellitus)|Diet, Healthy|Renal Function Disorder|Albuminuria",Drug: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas,"February 17, 2020","ASST FBF-Sacco P.O. Sacco/Fatebenefratelli e Oftalmico, Milano, Italy",https://ClinicalTrials.gov/show/NCT04272359
Principal Investigator,"Paolo Fiorina, MD, PhD",University of Milan,,NCT04365517,paolo fiorina,paolo,male,0.99,102713,266,NCT04365517,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,Not yet recruiting,No Results Available,"Covid19|Diabetes Mellitus, Type 2|CKD",Drug: Sitagliptin,"April 28, 2020","ASST FBF Sacco, Milan, Italy",https://ClinicalTrials.gov/show/NCT04365517
Principal Investigator,"Yi-Hsiang Huang, Ph.D","Taipei Veterans General Hospital, Taiwan",,NCT04349696,yi-hsiang huang,yi-hsiang,male,0.75,4,80,NCT04349696,Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide),Completed,No Results Available,Type 2 Diabetes Mellitus|Liver Dysfunction,Drug: Mitiglinide,"April 16, 2020","Chiayi Chang Gung Memorial Hospital, Chiayi City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04349696
Principal Investigator,"Wei-Ming Chen, MD",Chang Gung Memorial Hospital,,NCT04349696,wei-ming chen,wei-ming,male,1.0,5,80,NCT04349696,Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide),Completed,No Results Available,Type 2 Diabetes Mellitus|Liver Dysfunction,Drug: Mitiglinide,"April 16, 2020","Chiayi Chang Gung Memorial Hospital, Chiayi City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",https://ClinicalTrials.gov/show/NCT04349696
Principal Investigator,"Marc Y Donath, Prof. Dr. MD","University Hospital, Basel, Switzerland",,NCT04227769,marc y donath,marc,male,0.99,116213,82,NCT04227769,IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes,Recruiting,No Results Available,Diabetes Mellitus Type 2 in Obese|Inflammation|Metabolic Disease|Glucose Metabolism Disorders (Including Diabetes Mellitus),Drug: Anakinra Prefilled Syringe,"January 14, 2020","University Hospital Basel, Basel, Basel BS, Switzerland",https://ClinicalTrials.gov/show/NCT04227769
Principal Investigator,"Yves REZNIK, Pr",CHU Caen,,NCT04233229,yves reznik,yves,male,0.98,27837,83,NCT04233229,Evaluation of a Closed-loop Insulin Delivery System at Home With Tailored Home Care Services in Poorly Controlled DT2,Recruiting,No Results Available,Diabete Type 2,Device: t:slim X2 with Control-IQ|Other: home healthcare services|Other: usual care for daily insulin treatment,"January 18, 2020","CHU Caen, Caen, France",https://ClinicalTrials.gov/show/NCT04233229
Principal Investigator,"Steven J Russell, MD, PhD",Massachusetts General Hospital,,NCT04227626,steven j russell,steven,male,0.99,61542,84,NCT04227626,Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT,Not yet recruiting,No Results Available,Type 1 Diabetes|Type 2 Diabetes Treated With Insulin,Device: GlucoSTAT,"January 13, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04227626
Principal Investigator,"Kelly R Moore, MD",University of Colorado Anschutz Medical Center,,NCT04254653,kelly r moore,kelly,female,0.87,40778,88,NCT04254653,Diabetes Nutrition Education for American Indian and Alaska Native Communities,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: American Indian and Alaska Native What Can I Eat?,"February 5, 2020","Lakeport Tribal Health Consortium, Lakeport, California, United States|Indian Health Care Resource Center of Tulsa, Tulsa, Oklahoma, United States",https://ClinicalTrials.gov/show/NCT04254653
Principal Investigator,"Olena Mamykina, PhD",Columbia University,,NCT04226027,olena mamykina,olena,female,0.98,1535,89,NCT04226027,Dynamically Tailored Behavioral Interventions in Diabetes,Recruiting,No Results Available,Type 2 Diabetes,Behavioral: T2.coach,"January 13, 2020","Clinical Directors Network, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04226027
Principal Investigator,Hau Yee H CHUNG,Chinese University of Hong Kong,,NCT04348565,hau yee h chung,hau,male,0.78,270,90,NCT04348565,Diabetes Care Programme for Type 2 Diabetes Mellitus in Primary Care Setting,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Diabetes Care Programme,"April 16, 2020","Clinics of private general practitioners, Hong Kong, Hong Kong SAR, Hong Kong",https://ClinicalTrials.gov/show/NCT04348565
Principal Investigator,"Choon Ok Kim, M.D., PhD.",Severance Hospital,,NCT04334213,choon ok kim,choon,male,0.86,675,91,NCT04334213,"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150",Not yet recruiting,No Results Available,Type 2 Diabetes,"Drug: CKD-501|Drug: D745, D150|Drug: CKD-501, D745, D150","April 6, 2020",,https://ClinicalTrials.gov/show/NCT04334213
Principal Investigator,Min-gul Kim,Chonbuk National University Hospital,,NCT04322032,min-gul kim,min-gul,male,1.0,1,92,NCT04322032,Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389,Not yet recruiting,No Results Available,Type 2 Diabetes,Drug: Reference drug|Drug: Test drug,"March 26, 2020","Chonbuk National University Hospital, Jeonju, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04322032
Principal Investigator,"Silmara Leite, MD, PhD",Cline Research Center,,NCT04411277,silmara leite,silmara,female,0.99,131,95,NCT04411277,Time in Range (TIR) and Time Below Range (TBR) in Insulin-Treated Elderly Patients With Type 2 Diabetes,Not yet recruiting,No Results Available,Continuous Glucose Monitoring,Device: Application of the FreeStyle Libre Flash Glucose CGM.|Diagnostic Test: InBody 270 multifrequency bioimpedance,"June 2, 2020",,https://ClinicalTrials.gov/show/NCT04411277
Principal Investigator,"Min Soo Park, Ph.D. M.D",Severance Hospital,,NCT04246190,min soo park,min,male,0.57,7493,98,NCT04246190,A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396,Not yet recruiting,No Results Available,Type2 Diabetes Mellitus,Drug: CKD-501 and D759|Drug: CKD-396,"January 29, 2020","Yonsei University Severance Hospital, Soeul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04246190
Principal Investigator,"Min Soo Park, M.D., Ph.D.",Severance Hospital,,NCT04221360,min soo park,min,male,0.57,7493,100,NCT04221360,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375",Not yet recruiting,No Results Available,Type2 Diabetes Mellitus,Drug: CKD-375|Drug: D390,"January 9, 2020","Yonsei University Severance Hospital, Soeul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04221360
Principal Investigator,"Anhye Kim, Ph.D",CHA University,,NCT04431687,anhye kim,anhye,female,1.0,3,101,NCT04431687,"A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)",Not yet recruiting,No Results Available,Type 2 Diabetes Mellitus,"Drug: CKD 501|Drug: D759, D150|Drug: CKD-501, D759, D150","June 16, 2020",,https://ClinicalTrials.gov/show/NCT04431687
Principal Investigator,"Jia Miao, MD",West China Hospital,,NCT04324424,jia miao,jia,female,0.63,2077,104,NCT04324424,A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: HMS5552,"March 27, 2020","West China Hospital of Sichuan University, Chengdu, Sichuan, China",https://ClinicalTrials.gov/show/NCT04324424
Principal Investigator,"Ping Fu, MD",West China Hospital,,NCT04324424,ping fu,ping,male,0.53,1584,104,NCT04324424,A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers,Completed,No Results Available,Type 2 Diabetes Mellitus,Drug: HMS5552,"March 27, 2020","West China Hospital of Sichuan University, Chengdu, Sichuan, China",https://ClinicalTrials.gov/show/NCT04324424
Principal Investigator,"Bertrand CARIOU, Pr",Nantes Hospital University,,NCT04232293,bertrand cariou,bertrand,male,0.97,14197,109,NCT04232293,Screening of Liver Fibrosis in Patients With Type 2 Diabetes Mellitus,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|NAFLD|NASH",Diagnostic Test: Blood tests,"January 18, 2020","CHU d'Angers, Angers, France|CHU de Nantes, Nantes, France",https://ClinicalTrials.gov/show/NCT04232293
Principal Investigator,"Zhongming Liu, MD","Shanghai East Hospital, Shanghai Tongji University",,NCT04216849,zhongming liu,zhongming,male,0.93,15,111,NCT04216849,Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy,Recruiting,No Results Available,Type 2 Diabetes With Renal Manifestations,Biological: human umbilical cord mesenchymal stem cells|Other: saline,"January 3, 2020","Shanghai East Hospital, Shanghai, Shanghai, China",https://ClinicalTrials.gov/show/NCT04216849
Principal Investigator,"Rehab A Rayan, PharmD","High Institute of Public Health, Alexandria University",,NCT04236206,rehab a rayan,rehab,female,0.92,530,114,NCT04236206,Short Message Service for Type 2 Diabetes,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Mobile Phone Short Message Service,"January 22, 2020","Family Health Centers, Alexandria, Egypt",https://ClinicalTrials.gov/show/NCT04236206
Study Director,Rehab Werida,"Damanhour University, Faculty of Pharmacy",,NCT04240171,rehab werida,rehab,female,0.92,530,129,NCT04240171,Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin 5Mg Tab|Drug: Glimepiride 4Mg Tab,"January 27, 2020","Tanta University Hospital, Tanta, El-Gharbia, Egypt",https://ClinicalTrials.gov/show/NCT04240171
Study Chair,"Nashwa EL-Gharabawy, Lecturer",Tanta University,,NCT04240171,nashwa el-gharabawy,nashwa,female,0.98,183,129,NCT04240171,Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin 5Mg Tab|Drug: Glimepiride 4Mg Tab,"January 27, 2020","Tanta University Hospital, Tanta, El-Gharbia, Egypt",https://ClinicalTrials.gov/show/NCT04240171
Principal Investigator,Patrik Wennberg,Umeå University,,NCT04219800,patrik wennberg,patrik,male,0.99,19252,116,NCT04219800,Reduced Occupational Sitting in Type 2 Diabetes Using mHealth (Mobile Health),Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Patient-centered counselling and written material|Behavioral: mHealth,"January 7, 2020","Hertsöns Hälsocentral, Luleå, Norrbotten, Sweden",https://ClinicalTrials.gov/show/NCT04219800
Principal Investigator,"Giorgio Borretta, MD",Associazione Medici Endocrinologi,,NCT04295031,giorgio borretta,giorgio,male,0.99,41494,117,NCT04295031,Metformin in Older Adults With Type 2 Diabetes (AMEMET),Recruiting,No Results Available,"Diabetes Mellitus, Type 2",,"March 4, 2020","AME - Associazione Medici Endocrinologi, Udine, Italy",https://ClinicalTrials.gov/show/NCT04295031
Principal Investigator,"Dominique Hansen, prof. dr.",Hasselt University,,NCT04412798,dominique hansen,dominique,male,0.57,51398,118,NCT04412798,Orange Juice and Glycaemic Control in Type 2 Diabetes Mellitus,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: orange juice concentrate|Other: Sugar-sweetened orange-flavoured beverage|Other: Whole orange juice with skin removed,"June 2, 2020","Hasselt University, Hasselt, Belgium",https://ClinicalTrials.gov/show/NCT04412798
Principal Investigator,"Xiaoying Li, prof.",Fudan University,,NCT04374578,xiaoying li,xiaoying,female,0.89,81,119,NCT04374578,Effect of Dulaglutide on Improve Glycemic Variability With Type 2 Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Dulaglutide 1.5Mg/0.5Ml Inj Pen,"May 5, 2020",,https://ClinicalTrials.gov/show/NCT04374578
Study Chair,"Agnes Siew Ling Tey, Ph.D.",Abbott Nutrition,,NCT04303754,agnes siew ling tey,agnes,female,0.98,15854,120,NCT04303754,Diabetes-Specific Formula in Individuals With Type 2 Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Diabetes-Specific Formula|Other: Bread with Spread|Other: Mashed Potato,"March 11, 2020","Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04303754
Principal Investigator,"Norlaila Mustafa, MD.",Universiti Kebangsaan Malaysia Medical Centre,,NCT04303754,norlaila mustafa,norlaila,female,1.0,25,120,NCT04303754,Diabetes-Specific Formula in Individuals With Type 2 Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Diabetes-Specific Formula|Other: Bread with Spread|Other: Mashed Potato,"March 11, 2020","Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia",https://ClinicalTrials.gov/show/NCT04303754
Principal Investigator,"Weiping Jia, Doctor","Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital",,NCT04314622,weiping jia,weiping,male,0.71,55,123,NCT04314622,A Study of Supaglutide in Chinese Type 2 Diabetes Patients,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Supaglutide|Drug: Placebo,"March 19, 2020","The Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04314622
Principal Investigator,"Yuqian Bao, Doctor","Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital",,NCT04314622,yuqian bao,yuqian,female,0.92,13,123,NCT04314622,A Study of Supaglutide in Chinese Type 2 Diabetes Patients,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Supaglutide|Drug: Placebo,"March 19, 2020","The Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04314622
Principal Investigator,"Jianchao Quan, MPH, BM BCh","School of Public Health, The University of Hong Kong",,NCT04443842,jianchao quan,jianchao,male,0.85,13,124,NCT04443842,Behavioural Economics-based Incentives in Adults With Type 2 Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Financial and social incentives,"June 23, 2020","School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04443842
Principal Investigator,Jingya Yan,"WHO Health Promoting Hospital Office, The University of Hong Kong - Shenzhen Hospital, Shenzhen, China.",,NCT04342845,jingya yan,jingya,female,1.0,11,126,NCT04342845,Effectiveness of Motivational Interviewing on Improving Care for Patients With Type 2 Diabetes in China,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Experimental: Motivational interviewing Placebo Comparator: Traditional lectures,"April 13, 2020",,https://ClinicalTrials.gov/show/NCT04342845
Principal Investigator,Wei Liang,"Endocrinology Department, The University of Hong Kong - Shenzhen Hospital, Shenzhen, China.",,NCT04342845,wei liang,wei,male,0.72,5779,126,NCT04342845,Effectiveness of Motivational Interviewing on Improving Care for Patients With Type 2 Diabetes in China,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Experimental: Motivational interviewing Placebo Comparator: Traditional lectures,"April 13, 2020",,https://ClinicalTrials.gov/show/NCT04342845
Principal Investigator,"Francisco C. López Marquez, PhD","Universidad Autonoma de Coahuila, Centro de investigación Biomédica",,NCT04387045,francisco c. lópez marquez,francisco,male,0.99,98797,134,NCT04387045,Perceived Stress and Negative Thoughts With Biomarkers in People With Type 2 Diabetes Mellitus and Healthy Subjects,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Guilty feelings,"May 13, 2020","Facultad de medicina De la UADEC Unidad Torreón, Torreón, Coahuila De Zaragoza, Mexico",https://ClinicalTrials.gov/show/NCT04387045
Principal Investigator,"Ayman A. Zayed, MD",The University of Jordan School of Medicine,,NCT04237493,ayman a. zayed,ayman,male,0.97,11330,136,NCT04237493,Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan,Completed,No Results Available,"Diabetes Mellitus, Type 2","Drug: Metformin and Glimepiride (Low Dosage)|Drug: Metformin and Vildagliptin (Low Dosage)|Drug: Metformin and Insulin Glargine U100 (Low Dosage)|Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|Drug: Metformin and Glimepiride (Regular Dosage)|Drug: Metformin and Vildagliptin (Regular Dosage)|Drug: Metformin and Insulin Glargine U100 (Regular Dosage)|Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)","January 23, 2020","Jordan University Hospital, Amman, Amman Governorate, Jordan",https://ClinicalTrials.gov/show/NCT04237493
Principal Investigator,"Sandra Ofelia Hernández González, PhD",University of Guadalajara,,NCT04259606,sandra ofelia hernández gonzález,sandra,female,0.98,266121,143,NCT04259606,Effect of Cassia Cinnamon on Arterial Stiffness Parameters in Patients With Type 2 Diabetes Mellitus,Recruiting,No Results Available,Arterial Stiffness,Dietary Supplement: Cassia Cinnamon|Other: Calcined magnesia,"February 6, 2020","Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico",https://ClinicalTrials.gov/show/NCT04259606
Principal Investigator,"Vincent Wong, MD",Chinese University of Hong Kong,,NCT04241575,vincent wong,vincent,male,0.99,79107,144,NCT04241575,Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages,Recruiting,No Results Available,"Fatty Liver, Nonalcoholic|Diabetes Mellitus, Type 2",Diagnostic Test: Simple fibrosis scores and electronic reminder messages,"January 27, 2020","Prince of Wales Hospital, Hong Kong, Hong Kong",https://ClinicalTrials.gov/show/NCT04241575
Study Director,"Noemi Lois, Prof.",Queen´s University Belfast,,NCT04281186,noemi lois,noemi,female,0.99,21284,145,NCT04281186,Retinal and Cognitive Dysfunction in Type 2 Diabetes,Not yet recruiting,No Results Available,Retinal Function|Cognitive Dysfunction|Microperimetry,,"February 24, 2020",,https://ClinicalTrials.gov/show/NCT04281186
Study Director,"Rafael Simó, Prof",Vall Hebron Research Institute-VHIR,,NCT04281186,rafael simó,rafael,male,0.99,45829,145,NCT04281186,Retinal and Cognitive Dysfunction in Type 2 Diabetes,Not yet recruiting,No Results Available,Retinal Function|Cognitive Dysfunction|Microperimetry,,"February 24, 2020",,https://ClinicalTrials.gov/show/NCT04281186
Principal Investigator,"Alexandra Migdal, MD",Emory University,,NCT04276051,alexandra migdal,alexandra,female,0.98,122985,150,NCT04276051,Cryovagotomy Diabetes Trial,Not yet recruiting,No Results Available,Diabete Type 2|Diabetes Mellitus|Obesity,Device: Visual-ICE Cryoablation System|Behavioral: Lifestyle Intervention,"February 19, 2020","Emory University Hospital, Atlanta, Georgia, United States",https://ClinicalTrials.gov/show/NCT04276051
Principal Investigator,Assoc. Prof. Dr. Barakatun Nisak,"Faculty of Medicine and Health Sciences, Universiti Putra Malaysia",,NCT04234763,prof. dr. barakatun nisak,prof,male,0.93,851,153,NCT04234763,Postprandial Metabolites of Meal Challenge Test in Diabetes State,Enrolling by invitation,No Results Available,Type2 Diabetes|Postprandial Hyperglycemia,Behavioral: Strategies to lower postprandial hyperglycemia in T2D patients|Behavioral: Control group,"January 21, 2020","Universiti Putra Malaysia, Serdang, Selangor, Malaysia",https://ClinicalTrials.gov/show/NCT04234763
Principal Investigator,"Elizabeth Beale, MD",University of Southern California,,NCT04319003,elizabeth beale,elizabeth,female,0.99,31288,156,NCT04319003,Pilot Sugar Reduction Intervention in Kiritimati Teenagers,Completed,No Results Available,Type 2 Diabetes|Obesity,Behavioral: Sugar-reduction intervention,"March 24, 2020","University of Southern California, Los Angeles, California, United States|Kiritimati, London Village, Kiribati",https://ClinicalTrials.gov/show/NCT04319003
Principal Investigator,"Elizabeth Beale, MD","University of Southern California, Keck School of Medicine",,NCT04215328,elizabeth beale,elizabeth,female,0.99,31288,244,NCT04215328,Facilitated Release of Endogenous Enterokines,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Mixed-Meal|Dietary Supplement: Electrolyte Solution,"January 2, 2020","Roybal Diabetes Management Clinic, Los Angeles, California, United States",https://ClinicalTrials.gov/show/NCT04215328
Principal Investigator,"Elizabeth Joy, MD, MPH","Intermountain Health Care, Inc.",,NCT04313803,elizabeth joy,elizabeth,female,0.99,31288,263,NCT04313803,CGM in Utah Valley,Not yet recruiting,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Diabetes",Device: CGM,"March 18, 2020",,https://ClinicalTrials.gov/show/NCT04313803
Study Director,"Brad Isaacson, PhD, MBA, MSF, PMP","Intermountain Health Care, Inc.",,NCT04313803,brad isaacson,brad,male,0.99,10696,263,NCT04313803,CGM in Utah Valley,Not yet recruiting,No Results Available,"Diabetes Mellitus|Diabetes Mellitus, Type 2|Diabetes",Device: CGM,"March 18, 2020",,https://ClinicalTrials.gov/show/NCT04313803
Principal Investigator,"Neal D Barnard, MD",President,,NCT04222894,neal d barnard,neal,male,0.99,1772,158,NCT04222894,Hospital Workplace Nutrition Study,Recruiting,No Results Available,Overweight|Type2 Diabetes,Other: Plant-based diet|Other: Control Diet,"January 10, 2020","Sibley Memorial Hospital, Washington, District of Columbia, United States",https://ClinicalTrials.gov/show/NCT04222894
Principal Investigator,"Roy Eldor, MD PhD",Tel Aviv Medical Center,,NCT04447859,roy eldor,roy,male,0.98,21602,159,NCT04447859,16-week Flexible vs. 8-week Semaglutide Titration,Recruiting,No Results Available,Diabetes type2,Drug: Semaglutide|Other: label recommended titration,"June 25, 2020","Tel-Aviv Medical Center, Tel Aviv, Israel",https://ClinicalTrials.gov/show/NCT04447859
Study Chair,"Ivan Erzen, PhD","National Institute of Public Health, Slovenia",,NCT04230382,ivan erzen,ivan,male,0.99,117756,163,NCT04230382,The Proportion of Patients With Non-diagnosed Diabetes Type 2,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Diagnostic Test: Diagnosis of diabetes (OGTT),"January 18, 2020","National Institute of Public Health, Slovenia, Ljubljana, Slovenia",https://ClinicalTrials.gov/show/NCT04230382
Principal Investigator,"Jelka Zaletel, PhD","National Institute of Public Health, Slovenia",,NCT04230382,jelka zaletel,jelka,female,0.98,261,163,NCT04230382,The Proportion of Patients With Non-diagnosed Diabetes Type 2,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2",Diagnostic Test: Diagnosis of diabetes (OGTT),"January 18, 2020","National Institute of Public Health, Slovenia, Ljubljana, Slovenia",https://ClinicalTrials.gov/show/NCT04230382
Principal Investigator,"Emanuel Christ, Prof.","University Hospital, Basel, Switzerland",,NCT04216875,emanuel christ,emanuel,male,0.99,11961,169,NCT04216875,Best Practice Study of Diabetes Type 2 Management in Primary Care in Switzerland,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|Primary Care",Procedure: Best Practice Diabetes Management in Primary Care,"January 3, 2020","Hausarztmedizin KSSG, Saint Gallen, SG, Switzerland",https://ClinicalTrials.gov/show/NCT04216875
Principal Investigator,"Jessica R Wilson, MD, MS",University of Pennsylvania,,NCT04323189,jessica r wilson,jessica,female,0.98,144795,171,NCT04323189,Effects of Sitagliptin in Individuals With Genetically Decreased DPP4,Suspended,No Results Available,Genetics Disease|Type2 Diabetes|Heart Failure,Drug: Sitagliptin 100mg|Drug: Placebo Oral Tablet,"March 26, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",https://ClinicalTrials.gov/show/NCT04323189
Principal Investigator,"Adrian Camacho-Ortiz, PhD","Hospital Universitario ""Dr. Jose Eleuterio Gonzalez, UANL",,NCT04361097,adrian camacho-ortiz,adrian,male,0.99,90344,172,NCT04361097,Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease,Completed,No Results Available,Chronic Kidney Disease Due to Hypertension|Chronic Kidney Disease Due to Type 2 Diabetes Mellitus,Biological: Faecal microbiota transplant|Biological: Placebo,"April 24, 2020","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico",https://ClinicalTrials.gov/show/NCT04361097
Principal Investigator,Hua Bian,Shanghai Zhongshan Hospital,,NCT04283942,hua bian,hua,male,0.56,935,173,NCT04283942,Effect of Intermittent Calorie Restriction on NAFLD Patients With Disorders of Glucose Metabolism,Not yet recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease (NAFLD)|Disorders of Glucose Metabolism|Type 2 Diabetes|Impaired Glucose Regulation,Behavioral: Intermittent caloric restriction|Behavioral: 25kcal/kg/d diet,"February 25, 2020","Zhongshan Hospital, Fudan University, Shanghai, China",https://ClinicalTrials.gov/show/NCT04283942
Study Director,Xin Gao,Shanghai Zhongshan Hospital,,NCT04283942,xin gao,xin,female,0.52,1592,173,NCT04283942,Effect of Intermittent Calorie Restriction on NAFLD Patients With Disorders of Glucose Metabolism,Not yet recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease (NAFLD)|Disorders of Glucose Metabolism|Type 2 Diabetes|Impaired Glucose Regulation,Behavioral: Intermittent caloric restriction|Behavioral: 25kcal/kg/d diet,"February 25, 2020","Zhongshan Hospital, Fudan University, Shanghai, China",https://ClinicalTrials.gov/show/NCT04283942
Principal Investigator,Katrien Benhalima,UZ Leuven,,NCT04429958,katrien benhalima,katrien,female,0.99,2144,177,NCT04429958,The Belgian Diabetes in Pregnancy Follow-up Study,Not yet recruiting,No Results Available,Gestational Diabetes|Type2 Diabetes|Obesity,Other: GDM,"June 12, 2020","OLV-Alast, Aalst, Belgium|UZA, Antwerp, Belgium|OLV-Asse, Asse, Belgium|Imelda Bonheiden, Bonheiden, Belgium",https://ClinicalTrials.gov/show/NCT04429958
Principal Investigator,"Rozmin Jiwani, RN, PhD",University of Texas Health at San Antonio,,NCT04440449,rozmin jiwani,rozmin,female,0.6,5,178,NCT04440449,Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes,Recruiting,No Results Available,"Frailty|Weight, Body|Type 2 Diabetes",Behavioral: Lifestyle App,"June 19, 2020","The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",https://ClinicalTrials.gov/show/NCT04440449
Principal Investigator,"Kim Burchiel, MD",Oregon Health and Science University,,NCT04326192,kim burchiel,kim,female,0.56,51609,180,NCT04326192,Brown Adipose Tissue Activation by Spinal Cord Stimulation,Not yet recruiting,No Results Available,"Pain, Back|Obesity, Morbid|Type 2 Diabetes",Device: Research electrode,"March 30, 2020","Oregon Health & Science University, Portland, Oregon, United States",https://ClinicalTrials.gov/show/NCT04326192
Principal Investigator,"Stephen D. Persell, MD, MPH",Northwestern University,,NCT04289753,stephen d. persell,stephen,male,0.99,36980,182,NCT04289753,Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial,Not yet recruiting,No Results Available,Prostate Specific Antigen Screening|Asymptomatic Bacteriuria|Type 2 Diabetes,Behavioral: EHR clinical decision support nudges|Behavioral: Brief clinician education,"February 28, 2020","Northwestern Medicine, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04289753
Study Director,Bayer Study Director,Bayer,,NCT04383041,bayer study director,bayer,male,0.73,116,184,NCT04383041,Study to Learn More About Outcomes Reported by Patients Suffering From Type 2 Diabetes Using a Digital Data Collection Tool,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: No intervention,"May 11, 2020","Many locations, Multiple Locations, Germany",https://ClinicalTrials.gov/show/NCT04383041
Principal Investigator,"Isabelle METREAU, MD",Biofortis Mérieux NutriSciences,,NCT04423302,isabelle metreau,isabelle,female,0.99,89728,187,NCT04423302,Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT),Not yet recruiting,No Results Available,Prediabetic State|Diabetes type2|Dysglycemia,Dietary Supplement: TOTUM-63 3 intakes per day|Dietary Supplement: Placebo 3 intakes per day|Dietary Supplement: TOTUM-63 2 intakes per day,"June 9, 2020","CHU Amiens, Amiens, France|CH Arras, Arras, France|CIC Clermont Ferrand, Clermont-Ferrand, France|CEN Nutriment, Dijon, France|CHU Dijon, Dijon, France|Eurofins Optimed, Gières, France|CHU Grenoble, Grenoble, France|Institut Pasteur de Lille, Lille, France|CHU Lille, Lille, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|Unité de Recherche Clinique en Immunologie Lyon Sud, Pierre-Bénite, France|CHU Rouen, Rouen, France|Biofortis Mérieux NutriSciences, Saint-Herblain, France|Analyze & Realize, Berlin, Germany|Biotesys, Esslingen, Germany",https://ClinicalTrials.gov/show/NCT04423302
Principal Investigator,"Pål R. Njølstad, MD, PhD",Haukeland University Hospital,,NCT04239586,pål r. njølstad,pål,male,0.99,165,188,NCT04239586,Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes,Enrolling by invitation,No Results Available,"Maturity-Onset Diabetes of the Young, Type 3|Maturity Onset Diabetes of the Young, Type 1|Childhood Diabetes Mellitus|Insulin-dependent Diabetes Mellitus",Drug: Sulfonylurea,"January 27, 2020","Department of Pediatrics and Adolescents, Haukeland University Hospital, and Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway",https://ClinicalTrials.gov/show/NCT04239586
Study Chair,"Fei Li, Ph.D.",Abbott Nutrition,,NCT04345497,fei li,fei,male,0.54,1207,189,NCT04345497,Diabetes-Specific Formula on Long Term Glycemic Control,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Diabetes-Specific Formula|Other: Standard Of Care,"April 14, 2020","Hospital Canselor Tuanku Mukhriz, Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia|International Medical University, Kuala Lumpur, Malaysia|Klinik Kesihatan Seremban, Seremban, Malaysia|Phramongkutklao Hospital, Bangkok, Thailand|Rajavithi Hospital, Bangkok, Thailand",https://ClinicalTrials.gov/show/NCT04345497
Principal Investigator,"Al shymaa s abdelazem, lecturer",lecturer of basic sciences- faculty of physical therapy- cairo university,,NCT04219462,al shymaa s abdelazem,al,male,0.87,18287,191,NCT04219462,Effect of ESWT on ED in Type 2 Diabetics,Recruiting,No Results Available,"Erectile Dysfunction|Diabetes Mellitus, Type 2",Device: active extracorporeal shock wave|Device: sham extracorporeal shock wave,"January 7, 2020","Faculty of Physical Therapy, Giza, Egypt",https://ClinicalTrials.gov/show/NCT04219462
Principal Investigator,"JoAnn Lindenfeld, MD",Vanderbilt University Medical Center,,NCT04298229,joann lindenfeld,joann,female,0.83,1206,192,NCT04298229,Efficacy and Safety of Dapagliflozin in Acute Heart Failure,Recruiting,No Results Available,"Heart Failure|Diabetes Mellitus, Type 2",Drug: Dapagliflozin 10 MG|Other: Protocolized Diuretic Therapy,"March 6, 2020","University of Mississippi Medical Center, Jackson, Mississippi, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|Saint Thomas West Hospital, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04298229
Principal Investigator,"Sungsoo Park, MD, PhD",Korea University Anam Hospital,,NCT04284943,sungsoo park,sungsoo,male,0.98,110,193,NCT04284943,Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery,Recruiting,No Results Available,"Gastric Cancer|Diabetes Mellitus, Type 2",Procedure: Long limb Roux-en-Y reconstruction after subtotal gastrectomy|Procedure: Conventional Roux-en-Y reconstruction after subtotal gastrectomy|Procedure: Billroth II reconstruction after subtotal gastrectomy,"February 26, 2020","Korea University Anam Hospital, Seoul, Korea, Republic of",https://ClinicalTrials.gov/show/NCT04284943
Principal Investigator,"Pankaj Sharma, PhD",Ashford and St Peter's Hospitals NHS Foundation Trust,,NCT04231838,pankaj sharma,pankaj,male,0.99,2920,194,NCT04231838,Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems,Not yet recruiting,No Results Available,"Cardiovascular Risk Factor|Diabetes Mellitus, Type 2",Other: TOBACCO CIGARETTES|Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS),"January 18, 2020","Ashford and St Peters NHS Foundation Trust, Chertsey, Surrey, United Kingdom",https://ClinicalTrials.gov/show/NCT04231838
Principal Investigator,"Daniel van Raalte, MD PhD","Amsterdam UMC, location VU Medical Center",,NCT04238702,daniel van raalte,daniel,male,0.99,317409,197,NCT04238702,Renohemodynamic Effects of Combined empagliflOzin and LosARtan,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetic Kidney Disease",Drug: Empagliflozin 10 MG|Drug: Losartan 50Mg Tab|Other: Placebo,"January 23, 2020",,https://ClinicalTrials.gov/show/NCT04238702
Study Chair,"Vikkie Mustad, PhD",Abbott Nutrition,,NCT04230889,vikkie mustad,vikkie,female,0.86,50,201,NCT04230889,Evaluation of Glucose Control in Patients With Diabetes,Completed,No Results Available,Glycemic Control,Other: Usual Diet Group|Other: Group 1 Nutritional Shake|Other: Group 2 Nutritional Shake,"January 18, 2020","Radiant Research, Scottsdale, Arizona, United States|MB Clinical Research, Boca Raton, Florida, United States|Radiant Clinical Research, Pinellas Park, Florida, United States|Rocky Mountain Daibetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Health Partners Institute, International Diabetes Center, Minneapolis, Minnesota, United States|Radiant Research, Inc., Cincinnati, Ohio, United States",https://ClinicalTrials.gov/show/NCT04230889
Principal Investigator,Ugo Oliviero,Federico II University,,NCT04375943,ugo oliviero,ugo,male,0.97,7537,202,NCT04375943,Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study,Completed,No Results Available,Diabetes|Heart Failure,Drug: Antidiabetic,"May 6, 2020","Federico II University, Naples, Italy",https://ClinicalTrials.gov/show/NCT04375943
Principal Investigator,"Tatiana Karonova, PhD",Almazov National Medical Research Centre,,NCT04377399,tatiana karonova,tatiana,female,0.98,38772,203,NCT04377399,High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy,Completed,No Results Available,Diabetes Type 2|Diabetic Neuropathies|Vitamin D Deficiency,Drug: Vitamin D,"May 6, 2020","Almazov National Medical Research Centre, Saint Petersburg, Russian Federation",https://ClinicalTrials.gov/show/NCT04377399
Principal Investigator,"Frank L Greenway, MD",Pennington Biomedical Research Center,,NCT04306406,frank l greenway,frank,male,0.99,82391,206,NCT04306406,Molecular Mechanisms of Raspberries Effect on Insulin Resistance and Inflammation,Completed,No Results Available,Inflammation|Insulin Resistance,Other: Raspberries,"March 12, 2020",,https://ClinicalTrials.gov/show/NCT04306406
Principal Investigator,"Anna Solini, Prof",University of Pisa,,NCT04242758,anna solini,anna,female,0.98,383713,207,NCT04242758,Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy,"Active, not recruiting",No Results Available,Renal Function Disorder|Glucose Metabolism Disorders,Drug: Dapagliflozin 10 MG|Drug: Hydrochlorothiazide 12.5mg,"January 27, 2020","University of Pisa, Pisa, Italy",https://ClinicalTrials.gov/show/NCT04242758
Principal Investigator,seher ÇEVİK,İNÖNÜ ÜNİVERSİTESİ,,NCT04436666,seher çevi̇k,seher,female,0.97,6181,208,NCT04436666,"Virtual Reality, Ice Application and Self-injection and Self-test Fair, Pain and State Anxiety",Not yet recruiting,No Results Available,Injection Site Irritation|Fear of Pain,Device: motivational video production through virtual reality glasses|Other: Ice Application,"June 18, 2020","seher ÇEVİK, Malatya, Turkey",https://ClinicalTrials.gov/show/NCT04436666
Principal Investigator,"Nur Izgu, PhD",Hacettepe University,,NCT04287439,nur izgu,nur,female,0.9,24229,209,NCT04287439,"Relaxation and Meditation Techniques on Pain, Fatigue and Quality of Life",Completed,No Results Available,"Neuropathy, Diabetic",Behavioral: Progressive muscle relaxation|Behavioral: Mindfulness meditation|Other: Attention matched control,"February 27, 2020","Ankara University Medical Faculty Ibni Sina Hospital Endocrinology Outpatient Unit, Ankara, Turkey",https://ClinicalTrials.gov/show/NCT04287439
Principal Investigator,"Lia Bally, MD PhD","Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University, Unviersity of Bern",,NCT04361799,lia bally,lia,female,0.97,12635,210,NCT04361799,Perioperative Closed-loop Glucose Control,Not yet recruiting,No Results Available,Perioperative Hyperglycaemia|Insulin Therapy|Elective Surgery|Closed-Loop Glucose Control|Artificial Pancreas,Device: CamAPS|Drug: Standard insulin therapy,"April 24, 2020","Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern University Hospital, Bern, Switzerland",https://ClinicalTrials.gov/show/NCT04361799
Principal Investigator,"Jens Meier, MD",Kepler University Hospital -Dpt. of Anesthesiology & Intensive Care Medicine,,NCT04284722,jens meier,jens,male,0.99,23807,214,NCT04284722,Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery,Not yet recruiting,No Results Available,Hyperglycemia|Metformin|Type 2 Diabetes|Hyperlactatemia,Drug: Metformin Hydrochloride,"February 26, 2020",,https://ClinicalTrials.gov/show/NCT04284722
Principal Investigator,"Nazarii Kobyliak, PhD",Bogomolets National Medical University,,NCT04293731,nazarii kobyliak,nazarii,male,1.0,6,216,NCT04293731,Smectite Gel and Probiotic for Obesity and Insulin Resistance,Completed,No Results Available,Obesity|Insulin Resistance|Insulin Sensitivity|Type2 Diabetes Mellitus|Visceral Obesity,Dietary Supplement: Symbiter-Smectite|Dietary Supplement: Placebo,"March 3, 2020","Bogomolets National Medical University, Kyiv, Ukraine",https://ClinicalTrials.gov/show/NCT04293731
Study Chair,"Bridget Cassady, PhD, RDN, LD",Abbott Nutrition,,NCT04313920,bridget cassady,bridget,female,0.99,3520,217,NCT04313920,Study of a Carbohydrate Drink in Adults,Recruiting,No Results Available,Glycemic Response,Other: Nutritional Supplement,"March 18, 2020","Health Awareness, Inc., Jupiter, Florida, United States|Biofortis, Addison, Illinois, United States|Great Lakes Clinical Trials, Chicago, Illinois, United States",https://ClinicalTrials.gov/show/NCT04313920
Principal Investigator,"Lawrence Appel, MD, MPH",Johns Hopkins University,,NCT04286555,lawrence appel,lawrence,male,0.98,8119,220,NCT04286555,Dietary Approaches to Stop Hypertension for Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes|Diabetes type2|Type2 Diabetes|Type 2 Diabetes|Type II Diabetes|Hypertension|High Blood Pressure",Other: DASH4D diet|Other: comparison diet|Other: higher sodium|Other: lower sodium,"February 27, 2020","Johns Hopkins ProHealth, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04286555
Principal Investigator,"Hsin Chieh Yeh, PhD",Johns Hopkins University,,NCT04286555,hsin chieh yeh,hsin,male,0.58,169,220,NCT04286555,Dietary Approaches to Stop Hypertension for Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes|Diabetes type2|Type2 Diabetes|Type 2 Diabetes|Type II Diabetes|Hypertension|High Blood Pressure",Other: DASH4D diet|Other: comparison diet|Other: higher sodium|Other: lower sodium,"February 27, 2020","Johns Hopkins ProHealth, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04286555
Principal Investigator,"Nisa Maruthur, MD, MHS",Johns Hopkins University,,NCT04286555,nisa maruthur,nisa,female,0.96,3267,220,NCT04286555,Dietary Approaches to Stop Hypertension for Diabetes,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes|Diabetes type2|Type2 Diabetes|Type 2 Diabetes|Type II Diabetes|Hypertension|High Blood Pressure",Other: DASH4D diet|Other: comparison diet|Other: higher sodium|Other: lower sodium,"February 27, 2020","Johns Hopkins ProHealth, Baltimore, Maryland, United States",https://ClinicalTrials.gov/show/NCT04286555
Principal Investigator,"Jason L. Vassy, MD, MPH, SM",Harvard Medical School,,NCT04331535,jason l. vassy,jason,male,0.99,63418,222,NCT04331535,The Genomic Medicine at VA Study,Recruiting,No Results Available,Coronary Artery Disease|Atrial Fibrillation|Type 2 Diabetes|Colorectal Cancer|Breast Cancer|Prostate Cancer,Diagnostic Test: Polygenic risk score (PRS),"April 2, 2020","VA Boston Healthcare System, Boston, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04331535
Principal Investigator,"Nader Lessan, MD FRCP",Imperial College London Diabetes Center (ICLDC),,NCT04356898,nader lessan,nader,male,0.98,6855,223,NCT04356898,Ramadan Flash Glucose Monitoring Study,Completed,No Results Available,Diabetes Mellitus,Other: No intervention,"April 22, 2020","Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates|Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates",https://ClinicalTrials.gov/show/NCT04356898
Principal Investigator,Rolanda Lister,Vanderbilt University Medical Center,,NCT04406792,rolanda lister,rolanda,female,0.97,175,225,NCT04406792,Alternative Lifestyle Interventions in Vulnerable Ethnic Groups,Not yet recruiting,No Results Available,Gestational Diabetes|Pre-Eclampsia|Type2 Diabetes|Chronic Hypertension Complicating Pregnancy|Primary Hypertension After Pregnancy|Obesity,Behavioral: Alternative Lifestyle Interventions in Vulnerable Ethnic groups|Behavioral: Diabetes Prevention Program (DPP) online|Behavioral: Standard of Care,"May 28, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",https://ClinicalTrials.gov/show/NCT04406792
Principal Investigator,"Jesse C Stewart, PhD",Indiana University-Purdue University Indianapolis (IUPUI),,NCT04437485,jesse c stewart,jesse,male,0.91,9983,226,NCT04437485,eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk,Enrolling by invitation,No Results Available,Depression|Major Depressive Disorder|Dysthymic Disorder|Depressive Symptoms|Type 2 Diabetes|PreDiabetes|Insulin Resistance,Behavioral: Beating the Blues US™ (BtB)|Behavioral: Problem Solving Treatment in Primary Care (PST-PC)|Drug: Antidepressant Medications|Other: Active Control,"June 18, 2020","IUPUI Department of Psychology, Indianapolis, Indiana, United States",https://ClinicalTrials.gov/show/NCT04437485
Principal Investigator,"Quentin M Anstee, MBBS, PhD",Newcastle University,,NCT04442334,quentin m anstee,quentin,male,0.99,22654,227,NCT04442334,The European NAFLD Registry,Recruiting,No Results Available,"NAFLD|NASH|NASH - Nonalcoholic Steatohepatitis|Fibrosis, Liver|Steatosis of Liver|Hepatocellular Carcinoma|Cardiovascular Diseases|Type 2 Diabetes|Dyslipidaemia|Hypertension|Obesity|Other Associated Comorbidities",,"June 22, 2020","Universitair Ziekenhuis Antwerpen, Antwerp, Belgium|Helsinki University Hospital, Helsinki, Finland|Le Centre de Recherche Clinique (CRC) du CHU d'Angers, Angers, France|Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière, Paris, France|UNIVERSITÄTSKLINIKUM der RWTH Aachen, Aachen, Germany|Charité University Hospital Berlin, Berlin, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz, Mainz, Germany|Universitätsklinikums Würzburg, Würzburg, Germany|Laiko General Hospital of Athens, Athens, Greece|Polytechnic University of Marche, Ancona, Italy|Università degli Studi Milano, Milan, Italy|Università di Palermo, Palermo, Italy|Università Cattolica del Sacro Cuore, Rome, Italy|Department of Medical Sciences University of Torino, Turin, Italy|Amsterdam UMC, Amsterdam, Netherlands|Hospital de Santa Maria, Lisboa, Portugal|Vall d'Hebron University Hospital, Barcelona, Spain|Biodonostia Health Research Institute, Donostia, Spain|Puerta de Hierro University Hospital, Majadahonda, Spain|Marqués de Valdecilla University Hospital, Santander, Spain|Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital, Sevilla, Spain|HU Clínico de Valladolid, Valladolid, Spain|Karolinska Universitetssjukhuset, Huddinge, Sweden|Linköping University Hospital, Linköping, Sweden|Inselspital, University Hospital, Bern, Switzerland|University Hospitals Birmingham Nhs Foundation Trust, Birmingham, United Kingdom|Addenbrooke'S Hospital, Cambridge, United Kingdom|Queen Elizabeth Hospital, Gateshead, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Royal London Hospital, Barts Health NHS Trust, London, United Kingdom|St George's University Hospitals, London, United Kingdom|The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-upon Tyne, United Kingdom|Queen'S Medical Centre, Nottingham, United Kingdom|Oxford University Hospitals Nhs Foundation Trust, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom",https://ClinicalTrials.gov/show/NCT04442334
Principal Investigator,Alifah Nur'ain Haji Mat Rasil,University Brunei Darussalam,,NCT04217759,alifah nur'ain haji mat rasil,alifah,female,1.0,22,228,NCT04217759,Healthy Lifestyle Intervention on Diabetes Risk Reduction Among Bruneian Young Adults,Completed,No Results Available,"Overweight and Obesity|Risk Reduction|Diabetes Mellitus, Type 2",Behavioral: Healthy lifestyle intervention,"January 3, 2020","PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Brunei, Bandar Seri Begawan, Brunei Darussalam",https://ClinicalTrials.gov/show/NCT04217759
Study Director,"Andreas Moraitis, MD",Corcept Therapeutics,,NCT04308590,andreas moraitis,andreas,male,0.99,71365,233,NCT04308590,Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas,Recruiting,No Results Available,Hypercortisolism,Drug: relacorilant|Other: placebo,"March 16, 2020","Site 01, Wilmington, North Carolina, United States|Site 02, Summerville, South Carolina, United States|Site 03, El Paso, Texas, United States|Site 05, Fort Worth, Texas, United States|Site 04, Shavano Park, Texas, United States",https://ClinicalTrials.gov/show/NCT04308590
Study Director,"Andreas G Moraitis, MD",Corcept Therapeutics,,NCT04373265,andreas g moraitis,andreas,male,0.99,71365,234,NCT04373265,Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production,Not yet recruiting,No Results Available,Adrenocortical Carcinoma,Drug: Relacorilant|Drug: Pembrolizumab,"May 4, 2020",,https://ClinicalTrials.gov/show/NCT04373265
Principal Investigator,"Andreas Pfützner, Prof. Dr. Dr.",Pfützner Science & Health Institute GmbH,,NCT04340648,andreas pfützner,andreas,male,0.99,71365,272,NCT04340648,"Measurement Algorithm Control, Optimization, and Performance Evaluation of the Vital USA GlucoseDetect",Completed,No Results Available,Diabetes Mellitus,Device: Vital GlucoseDetect,"April 9, 2020","Pfützner Science & Health Institute GmbH, Mainz, Rhineland-Palatinate, Germany",https://ClinicalTrials.gov/show/NCT04340648
Principal Investigator,"Rosa Flores, MD",Institut Català de la Salut,,NCT04244110,rosa flores,rosa,female,0.98,77424,235,NCT04244110,Pilot for the Analysis of Usability in the Use of the Diacare Platform for People With Type 2 DM and Their Professionals,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",,"January 28, 2020","CAP Bellvitge, Hospitalet de Llobregat, Barcelona, Spain",https://ClinicalTrials.gov/show/NCT04244110
Principal Investigator,"Athena Philis-Tsimikas, MD",Scripps Whittier Diabetes Institute,,NCT04269655,athena philis-tsimikas,athena,female,0.95,1376,237,NCT04269655,Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM),Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: Cloud-Based Continuous Glucose Monitoring,"February 17, 2020","Scripps Whittier Diabetes Institute, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT04269655
Study Director,"Addie Fortmann, PhD",Scripps Whittier Diabetes Institute,,NCT04269655,addie fortmann,addie,male,0.59,283,237,NCT04269655,Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM),Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Device: Cloud-Based Continuous Glucose Monitoring,"February 17, 2020","Scripps Whittier Diabetes Institute, La Jolla, California, United States",https://ClinicalTrials.gov/show/NCT04269655
Principal Investigator,"Stephanie L Shimada, PhD","Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA",,NCT04227379,stephanie l shimada,stephanie,female,0.98,68107,238,NCT04227379,Diabetes Disparities: Texting to Extend Treatment (DD-TXT),Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Intervention 1- DD-TXT|Behavioral: Comparison - DSE,"January 13, 2020","North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States",https://ClinicalTrials.gov/show/NCT04227379
Study Chair,"Lai, M.D.",Beijing Anzhen Hospital,,NCT04340908,lai,lai,female,0.52,2051,243,NCT04340908,Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Cardiac Surgery",Drug: Dapagliflozin 10 MG|Drug: Placebos,"April 10, 2020","Beijing Anzhen Hospital, Capital Mediacal University, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04340908
Study Director,"Guo, M.D.",Beijing Anzhen Hospital,,NCT04340908,guo,guo,male,0.7,648,243,NCT04340908,Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Cardiac Surgery",Drug: Dapagliflozin 10 MG|Drug: Placebos,"April 10, 2020","Beijing Anzhen Hospital, Capital Mediacal University, Beijing, Beijing, China",https://ClinicalTrials.gov/show/NCT04340908
Principal Investigator,"Amelia Guadalupe Grau, PhD",Technical University of Madrid,,NCT04332302,amelia guadalupe grau,amelia,female,0.98,9165,245,NCT04332302,Power Strength Training in Type 2 Diabetic Mellitus Older Adults,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2|Frailty",Other: Power resistance training,"April 2, 2020","Instituto Nacional de Educación Física, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04332302
Study Chair,"Carmen Ramírez Castillejo, PhD",Technical University of Madrid,,NCT04332302,carmen ramírez castillejo,carmen,female,0.98,103801,245,NCT04332302,Power Strength Training in Type 2 Diabetic Mellitus Older Adults,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2|Frailty",Other: Power resistance training,"April 2, 2020","Instituto Nacional de Educación Física, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04332302
Study Director,"Marcela González Gross, Professor",Technical University of Madrid,,NCT04332302,marcela gonzález gross,marcela,female,0.99,23039,245,NCT04332302,Power Strength Training in Type 2 Diabetic Mellitus Older Adults,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2|Frailty",Other: Power resistance training,"April 2, 2020","Instituto Nacional de Educación Física, Madrid, Spain",https://ClinicalTrials.gov/show/NCT04332302
Principal Investigator,Chen,The Ninth People's Hospital Affiliated to Shanghai Jiaotong University,,NCT04357392,chen,chen,male,0.62,5003,248,NCT04357392,Effect of Glucocorticoid on Exogenous Insulin Antibody Syndrome,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Drug: Prednisone,"April 22, 2020",,https://ClinicalTrials.gov/show/NCT04357392
Principal Investigator,"Juan Li, M.D.",The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,,NCT04354090,juan li,juan,male,0.98,274814,249,NCT04354090,"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09",Completed,No Results Available,"Diabetes Mellitus, Type 2",Drug: JY09,"April 21, 2020","Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China",https://ClinicalTrials.gov/show/NCT04354090
Principal Investigator,Marabelle Heng,Singapore General Hospital,,NCT04278742,marabelle heng,marabelle,female,1.0,6,254,NCT04278742,A Collaborative Approach in Diabetes Foot Education - A Pragmatic Randomised Control Trial,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|Neuropathy;Peripheral",Other: Patient education,"February 20, 2020","Singapore General Hospital, Singapore, Singapore",https://ClinicalTrials.gov/show/NCT04278742
Principal Investigator,"Enoch Huang, MD",Legacy Emanuel Medical Center,,NCT04261738,enoch huang,enoch,male,0.98,959,257,NCT04261738,Effects of HBO on Patients With DM,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Device: Hyperbaric Oxygen,"February 10, 2020",,https://ClinicalTrials.gov/show/NCT04261738
Principal Investigator,"Amira Mohamady, MD",Benha university- Qaluibya- Egypt,,NCT04322240,amira mohamady,amira,female,0.97,11084,259,NCT04322240,Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy,Not yet recruiting,No Results Available,"Diabetic Polyneuropathy|Diabetes Mellitus, Type 2",Drug: Alpha lipoic acid,"March 26, 2020","Benha University Hospital, Banhā, Qalubiya, Egypt",https://ClinicalTrials.gov/show/NCT04322240
Principal Investigator,"Caroline Richard, PhD, RD",University of Alberta,,NCT04291391,caroline richard,caroline,female,0.98,64753,261,NCT04291391,The Alberta NutrIMM Study - Nutrition and Immunity,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Obesity",Other: North American Diet,"March 2, 2020","University of Alberta, Edmonton, Alberta, Canada",https://ClinicalTrials.gov/show/NCT04291391
Principal Investigator,"Naftali Stern, MD",Tel-Aviv Sourasky Medical Center,,NCT04406402,naftali stern,naftali,male,0.82,68,264,NCT04406402,L-arginine and Asymmetric Dimethylarginine (ADMA) and Lifestyle Protocols,Completed,No Results Available,"Diabetes Mellitus, Type 2|Obesity|Arginine|Asymmetric Dimethylarginine",Behavioral: Acute dietary protocols and lifestyle modification,"May 28, 2020","Diabetes Unit, E. Wolfson Medical Center, Holon, Israel",https://ClinicalTrials.gov/show/NCT04406402
Principal Investigator,"Ali Aminian, MD",The Cleveland Clinic,,NCT04263376,ali aminian,ali,male,0.95,319583,267,NCT04263376,Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD,Enrolling by invitation,No Results Available,"Obesity|Diabetes Mellitus, Type 2|NAFLD",,"February 10, 2020","Cleveland Clinic Foundation, Cleveland, Ohio, United States",https://ClinicalTrials.gov/show/NCT04263376
Principal Investigator,"Stewart Harris, MD MPH",Western University,,NCT04219514,stewart harris,stewart,male,0.98,2720,271,NCT04219514,Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models,"Active, not recruiting",No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",,"January 7, 2020","Ipsos, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04219514
Principal Investigator,"Alexandria Ratzki-Leewing, PhD(c) MSc",Western University,,NCT04219514,alexandria ratzki-leewing,alexandria,female,0.91,325,271,NCT04219514,Investigating Novel Predictions of Hypoglycemia Occurrence in Real-world Models,"Active, not recruiting",No Results Available,"Hypoglycemia|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",,"January 7, 2020","Ipsos, New York, New York, United States",https://ClinicalTrials.gov/show/NCT04219514
